Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17920649 | 0.83 | LMNA (0.56) | GSK3BKDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL23197679 | 0.83 | TDP1 (0.56) | GSK3BKDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL3077231 | 0.77 | ADORA2A (0.48) | GSK3BKDM4EALDH1A1HSD17B10GAA | |
| SCHEMBL2319851 | 0.76 | TDP1 (0.48) | GSK3BKDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL2199459 | 0.76 | PTGS1 (0.55) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL13680521 | 0.75 | CYP2A6 (0.57) | KDM4EALDH1A1HSD17B10NPC1HPGD | |
| SCHEMBL12669250 | 0.74 | TDP1 (0.46) | GSK3BKDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL12578009 | 0.74 | TDP1 (0.67) | GSK3BKDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL14781240 | 0.73 | KDM4E (0.46) | GSK3BKDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL5539598 | 0.73 | GSK3B (0.57) | GSK3BKDM4EALDH1A1SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | claimed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | claimed |
| EP-2934538-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2021-03-31 | — | — | EP | disclosed |
| US-9932330-B2 | Piperazine derivatives for treating disorders | THE UNIVERSITY OF NOTTINGHAM (GB) | 2018-04-03 | — | — | US | disclosed |
| US-20180044331-A1 | PIPERAZINE DERIVATIVES FOR TREATING DISORDERS | EXONATE LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| US-9796707-B2 | Piperazine derivatives for treating disorders | THE UNIVERSITY OF NOTTINGHAM (GB) | 2017-10-24 | — | — | US | disclosed |
| US-20170267670-A1 | PIPERAZINE DERIVATIVES FOR TREATING DISORDERS | EXONATE LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-9708308-B2 | Factor IXa inhibitors | MERCK SHARP DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9695160-B2 | Piperazine derivatives for treating disorders | THE UNIVERSITY OF NOTTINGHAM (GB) | 2017-07-04 | — | — | US | disclosed |
| WO-2014120346-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20130252962-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2013-09-26 | — | — | US | disclosed |
| US-8415370-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-04-09 | — | — | US | disclosed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | disclosed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | disclosed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252962-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | GSK3B 350/4885KDM4E 4619/4885ALDH1A1 1020/4885 |
| US-20180044331-A1 | PIPERAZINE DERIVATIVES FOR TREATING DISORDERS | PGF, GAP43, VHL | GSK3B 2935/4885KDM4E 2903/4885ALDH1A1 1203/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | GSK3B 350/4885KDM4E 4619/4885ALDH1A1 1020/4885 |
| US-20170267670-A1 | PIPERAZINE DERIVATIVES FOR TREATING DISORDERS | PGF, GAP43, VHL | GSK3B 2935/4885KDM4E 2903/4885ALDH1A1 1203/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | GSK3B 360/4885KDM4E 4646/4885ALDH1A1 1005/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | GSK3B 350/4885KDM4E 4619/4885ALDH1A1 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.